{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:30:29Z","timestamp":1740115829344,"version":"3.37.3"},"reference-count":96,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43 TW009114"],"award-info":[{"award-number":["D43 TW009114"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","award":["18T-003","19T-002"],"award-info":[{"award-number":["18T-003","19T-002"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","biologicalpsychiatryjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.biopsych.2024.06.022","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T06:37:28Z","timestamp":1719643048000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Schizophrenia Interactome\u2013Derived Repurposable Drugs and Randomized Controlled Trials of Two Candidates"],"prefix":"10.1016","volume":"96","author":[{"given":"Madhavi K.","family":"Ganapathiraju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Triptish","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribeth","family":"Wesesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwajit L.","family":"Nimgaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2024.06.022_bib1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: Findings From the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2024.06.022_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease \u2013 A non-systematic review of epidemiology, possible causes, and interventions","volume":"5","author":"Ringen","year":"2014","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.31887\/DCNS.2002.4.4\/mackenheil","article-title":"Developments in antipsychotic therapy with regard to hypotheses for schizophrenia","volume":"4","author":"Ackenheil","year":"2002","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.biopsych.2024.06.022_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ddr.21337","article-title":"Improving current treatments for schizophrenia","volume":"77","author":"Maric","year":"2016","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.biopsych.2024.06.022_bib6","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: Past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.biopsych.2024.06.022_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40263-017-0428-x","article-title":"Managing negative symptoms of schizophrenia: How far have we come?","volume":"31","author":"Kantrowitz","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2024.06.022_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.biopsych.2024.06.022_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/wps.21056","article-title":"The future of psychopharmacology: A critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents","volume":"22","author":"Correll","year":"2023","journal-title":"World Psychiatry"},{"year":"2014","series-title":"Schizophrenia and Its Treatment: Where Is the Progress?","author":"Kurtz","key":"10.1016\/j.biopsych.2024.06.022_bib10"},{"key":"10.1016\/j.biopsych.2024.06.022_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \u201cjust the facts\u201d and what we know in 2008. 2. Epidemiology and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophr Res"},{"issue":"suppl","key":"10.1016\/j.biopsych.2024.06.022_bib12","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"2nd ed 161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A\u00a0systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"J\u00e4\u00e4skel\u00e4inen","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2024.06.022_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1004640408501","article-title":"Treatment refractory schizophrenia","volume":"71","author":"Lindenmayer","year":"2000","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.biopsych.2024.06.022_bib15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2007.04.001","article-title":"Treatment-resistant schizophrenia","volume":"30","author":"Elkis","year":"2007","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.biopsych.2024.06.022_bib16","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12597","article-title":"NIMH drug trials for schizophrenia","volume":"80","author":"Torrey","year":"2019","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib17","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1007\/s11033-023-08241-7","article-title":"Understanding translational research in schizophrenia: A novel insight into animal models","volume":"50","author":"Malik","year":"2023","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.biopsych.2024.06.022_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-23274-9_8","article-title":"Muscarinic agonists and antagonists in schizophrenia: Recent therapeutic advances and future directions","volume":"208","author":"Bolbecker","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109261","article-title":"Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats","volume":"231","author":"Synan","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2024.06.022_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: A narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2024.06.022_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/neu.2020.44","article-title":"Adjunctive yoga training for persons with schizophrenia: Who benefits?","volume":"33","author":"Bhatia","year":"2021","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.biopsych.2024.06.022_bib23","first-page":"172","article-title":"The cost of new drug discovery and development","volume":"4","author":"Dickson","year":"2004","journal-title":"Discov Med"},{"key":"10.1016\/j.biopsych.2024.06.022_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J\u00a0Health Econ"},{"key":"10.1016\/j.biopsych.2024.06.022_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: Therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biopsych.2024.06.022_bib26","first-page":"233","article-title":"The NIMH \u2018fast-fail trials\u2019 (FAST) initiative: Rationale, promise, and progress","volume":"34","author":"Grabb","year":"2020","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.biopsych.2024.06.022_bib27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0006-3223(90)90602-X","article-title":"Drug trials and heterogeneity in schizophrenia: The mean is not the end","volume":"28","author":"Wolkowitz","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/ACM.0000000000000528","article-title":"Project development teams: A novel mechanism for accelerating translational research","volume":"90","author":"Sajdyk","year":"2015","journal-title":"Acad Med"},{"key":"10.1016\/j.biopsych.2024.06.022_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.schres.2022.03.013","article-title":"Multimorbidity landscape of schizophrenia: Insights from meta-analysis of genome wide association studies","volume":"243","author":"Gawde","year":"2022","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2024.06.022_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neubiorev.2019.04.015","article-title":"Postmortem brain tissue as an underutilized resource to study the molecular pathology of neuropsychiatric disorders across different ethnic populations","volume":"102","author":"Vornholt","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2024.06.022_bib31","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-023-02005-2","article-title":"The molecular pathology of schizophrenia: An overview of existing knowledge and new directions for future research","volume":"28","author":"Nakamura","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: A next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2024.06.022_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2017.29","article-title":"A\u00a0standard database for drug repositioning","volume":"4","author":"Brown","year":"2017","journal-title":"Sci Data"},{"issue":"4","key":"10.1016\/j.biopsych.2024.06.022_bib96","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/bib\/bbw136","article-title":"Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning","volume":"19","author":"Shameer","year":"2018","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.biopsych.2024.06.022_bib34","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: Towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopsych.2024.06.022_bib35","first-page":"1","article-title":"A\u00a0new method for computational drug repositioning using drug pairwise similarity","volume":"2012","author":"Li","year":"2012","journal-title":"Proceedings (IEEE Int Conf Bioinformatics Biomed)"},{"key":"10.1016\/j.biopsych.2024.06.022_bib36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/msb.2011.26","article-title":"PREDICT: A method for inferring novel drug indications with application to personalized medicine","volume":"7","author":"Gottlieb","year":"2011","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib37","article-title":"Predicting drug-disease association based on ensemble strategy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Genet"},{"issue":"suppl 26","key":"10.1016\/j.biopsych.2024.06.022_bib38","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12859-019-3283-6","article-title":"Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning","volume":"20","author":"Wang","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.biopsych.2024.06.022_bib39","article-title":"DrugRepo: A novel approach to repurposing drugs based on chemical and genomic features","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2024.06.022_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48307-w","article-title":"Potentially repurposable drugs for schizophrenia identified from its interactome","volume":"9","author":"Karunakaran","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2024.06.022_bib41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jcmm.12722","article-title":"Gene mutation-based and specific therapies in precision medicine","volume":"20","author":"Wang","year":"2016","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.biopsych.2024.06.022_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41398-021-01243-8","article-title":"Functional patient-derived cellular models for neuropsychiatric drug discovery","volume":"11","author":"Lago","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41386-023-01690-5","article-title":"Finding new and better treatments for psychiatric disorders","volume":"49","author":"Paul","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2024.06.022_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110637","article-title":"Candidates for drug repurposing to address the cognitive symptoms in schizophrenia","volume":"120","author":"Koch","year":"2023","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.biopsych.2024.06.022_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bib\/bbv020","article-title":"A\u00a0survey of current trends in computational drug repositioning","volume":"17","author":"Li","year":"2016","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.biopsych.2024.06.022_bib47","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/2159-8290.CD-13-0183","article-title":"A\u00a0drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors","volume":"3","author":"Jahchan","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.biopsych.2024.06.022_bib48","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","article-title":"Network-based approach to prediction and population-based validation of in silico drug repurposing","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2024.06.022_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/npjschz.2016.12","article-title":"Schizophrenia interactome with 504 novel protein\u2013protein interactions","volume":"2","author":"Ganapathiraju","year":"2016","journal-title":"NPJ Schizophr"},{"key":"10.1016\/j.biopsych.2024.06.022_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/npjschz.2016.25","article-title":"Schizophrenia interactome: Fully-labeled interactome network","volume":"2","author":"Ganapathiraju","year":"2016","journal-title":"npj Schizophr"},{"key":"10.1016\/j.biopsych.2024.06.022_bib51","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: A comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopsych.2024.06.022_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/data2020015","article-title":"Demonstration study: A protocol to combine online tools and databases for identifying potentially repurposable drugs","volume":"2","author":"Chattopadhyay","year":"2017","journal-title":"Data"},{"key":"10.1016\/j.biopsych.2024.06.022_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: State of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.biopsych.2024.06.022_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuropharm.2014.12.032","article-title":"The mast cell stabilizer sodium cromoglycate reduces histamine release and status epilepticus-induced neuronal damage in the rat hippocampus","volume":"92","author":"Valle-Dorado","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2024.06.022_bib56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.12659\/MSMBR.893093","article-title":"Mast cells and neuroinflammation","volume":"20","author":"Dong","year":"2014","journal-title":"Med Sci Monit Basic Res"},{"key":"10.1016\/j.biopsych.2024.06.022_bib57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fpsyt.2017.00083","article-title":"Neurovascular unit dysfunction and blood-brain barrier hyperpermeability contribute to schizophrenia neurobiology: A theoretical integration of clinical and experimental evidence","volume":"8","author":"Najjar","year":"2017","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib58","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/13543784.2022.2095261","article-title":"ALZT-OP1: An experimental combination regimen for the treatment of Alzheimer\u2019s disease","volume":"31","author":"Lozupone","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.biopsych.2024.06.022_bib59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14728214.2020.1808621","article-title":"Anti-amyloid-beta protein agents for the treatment of Alzheimer\u2019s disease: An update on emerging drugs","volume":"25","author":"Lozupone","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.biopsych.2024.06.022_bib60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.intimp.2015.02.004","article-title":"Nasal sodium cromoglycate (Lomusol) modulates the early phase reaction of mild to\u00a0moderate persistent allergic rhinitis in patients mono-sensitized to house\u00a0dust mite: A preliminary study","volume":"26","author":"Lejeune","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2125.1999.00979.x","article-title":"Plasma concentrations of disodium cromoglycate after various inhalation methods in healthy subjects","volume":"48","author":"Kato","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib62","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.2174\/138161210793429797","article-title":"Carbonic anhydrase inhibition\/activation: Trip of a scientist around the world in the search of novel chemotypes and drug targets","volume":"16","author":"Supuran","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.biopsych.2024.06.022_bib63","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bmcl.2004.12.052","article-title":"Carbonic Anhydrase Inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides","volume":"15","author":"Vullo","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"90","key":"10.1016\/j.biopsych.2024.06.022_bib64","first-page":"475","article-title":"Carbonic anhydrase in the nervous system","author":"Cammer","year":"2000","journal-title":"EXS"},{"key":"10.1016\/j.biopsych.2024.06.022_bib65","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/aps.2017.172","article-title":"GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia","volume":"39","author":"Xu","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.biopsych.2024.06.022_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22009","article-title":"Carbonic anhydrase inhibitor acetazolamide shifts synaptic vesicle recycling to a fast mode at the mouse neuromuscular junction","volume":"71","author":"Bertone","year":"2017","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2024.06.022_bib67","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.mp.4000696","article-title":"Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium","volume":"5","author":"Johnston-Wilson","year":"2000","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib68","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1002\/pmic.200500069","article-title":"Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes","volume":"6","author":"Beasley","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.biopsych.2024.06.022_bib69","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1590\/1414-431x20154550","article-title":"Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder","volume":"48","author":"Song","year":"2015","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.biopsych.2024.06.022_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/13813455.2013.863359","article-title":"Antipsychotic agents screened as human carbonic anhydrase I and II inhibitors","volume":"120","author":"Erzengin","year":"2014","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.biopsych.2024.06.022_bib71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/brainsci13010140","article-title":"Acetazolamide for bipolar disorders: A scoping review","volume":"13","author":"Strawbridge","year":"2023","journal-title":"Brain Sci"},{"issue":"7","key":"10.1016\/j.biopsych.2024.06.022_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/S0007125000291496","article-title":"The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundations","volume":"Suppl","author":"Andreasen","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00004714-198802000-00031","article-title":"Acetazolamide and thiamine (A+T): A preliminary report of an ancillary therapy for chronic mental illness","volume":"8","author":"Sacks","year":"1988","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10401239409148987","article-title":"Acetazolamide in bipolar affective disorders","volume":"6","author":"Hayes","year":"1994","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib75","first-page":"425","article-title":"Antipsychotic and prophylactic effects of acetazolamide (diamox) on atypical psychosis","volume":"38","author":"Inoue","year":"1984","journal-title":"Folia Psychiatr Neurol Jpn"},{"key":"10.1016\/j.biopsych.2024.06.022_bib76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.10.018","article-title":"Current state and future perspective of drug repurposing in malignant glioma","volume":"68","author":"Siegelin","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib77","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2024.06.022_bib78","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14022","article-title":"Treating insulin Resistance with metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (the Trio-BD Study): A Randomized, Quadruple-Masked, Placebo-Controlled Clinical Trial","volume":"83","author":"Calkin","year":"2022","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2024.06.022_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000423","article-title":"Drug discovery using chemical systems biology: Repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis","volume":"5","author":"Kinnings","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biopsych.2024.06.022_bib81","doi-asserted-by":"crossref","DOI":"10.2174\/1871526521666210301143441","article-title":"COVID-19: Potential repurposing drugs","volume":"22","author":"Leowattana","year":"2022","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.biopsych.2024.06.022_bib82","first-page":"259","article-title":"Repurposing antifungal drugs for cancer therapy","volume":"48","author":"Weng","year":"2023","journal-title":"J\u00a0Adv Res"},{"key":"10.1016\/j.biopsych.2024.06.022_bib83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000528274","article-title":"New and repurposed drugs for the treatment of active tuberculosis: An update for clinicians","volume":"102","author":"Aguilar Diaz","year":"2023","journal-title":"Respiration"},{"key":"10.1016\/j.biopsych.2024.06.022_bib84","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1001\/jama.2023.23363","article-title":"Higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19: The ACTIV-6 randomized clinical trial","volume":"330","author":"Stewart","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2024.06.022_bib85","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.neubiorev.2013.03.022","article-title":"Innovative solutions to novel drug development in mental health","volume":"37","author":"Insel","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2024.06.022_bib86","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14737175.2015.1066675","article-title":"Acetazolamide for the treatment of idiopathic intracranial hypertension","volume":"15","author":"Supuran","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.biopsych.2024.06.022_bib87","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","article-title":"Carbonic anhydrase: Chemistry, physiology, and inhibition","volume":"47","author":"Maren","year":"1967","journal-title":"Physiol Rev"},{"key":"10.1016\/j.biopsych.2024.06.022_bib88","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neubiorev.2017.05.001","article-title":"Mast cells in neuroinflammation and brain disorders","volume":"79","author":"Hendriksen","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"year":"1993","series-title":"The Extra Pharmacopoeia","author":"Martindale","key":"10.1016\/j.biopsych.2024.06.022_bib89"},{"year":"1991","series-title":"Therapeutic Drugs","author":"Collin","key":"10.1016\/j.biopsych.2024.06.022_bib90"},{"key":"10.1016\/j.biopsych.2024.06.022_bib91","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/JCP.0000000000000529","article-title":"A\u00a0pharmacokinetic study examining acetazolamide as a novel adherence marker for clinical trials","volume":"36","author":"Hampson","year":"2016","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2024.06.022_bib92","first-page":"160","article-title":"Carbonic anhydrase inhibition. VII. Carbonic anhydrase inhibition and anticonvulsant effect","volume":"121","author":"Gray","year":"1957","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2024.06.022_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051073","article-title":"Different methods and formulations of drugs and vaccines for nasal administration","volume":"14","author":"Tai","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopsych.2024.06.022_bib94","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.2014.3312","article-title":"Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: The idiopathic intracranial hypertension treatment trial","volume":"311","author":"Wall","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2024.06.022_bib95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/WNO.0000000000000322","article-title":"Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial","volume":"36","author":"ten Hove","year":"2016","journal-title":"J\u00a0Neuroophthalmol"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322324014264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322324014264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T10:25:58Z","timestamp":1734431158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322324014264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0006322324014264"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2024.06.022","relation":{},"ISSN":["0006-3223"],"issn-type":[{"type":"print","value":"0006-3223"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Schizophrenia Interactome\u2013Derived Repurposable Drugs and Randomized Controlled Trials of Two Candidates","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2024.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}